Cahaba Wealth Management Inc. Increases Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Cahaba Wealth Management Inc. raised its stake in Merck & Co., Inc. (NYSE:MRKFree Report) by 15.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,449 shares of the company’s stock after purchasing an additional 456 shares during the period. Cahaba Wealth Management Inc.’s holdings in Merck & Co., Inc. were worth $376,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Ruedi Wealth Management Inc. grew its position in shares of Merck & Co., Inc. by 180.2% during the third quarter. Ruedi Wealth Management Inc. now owns 311 shares of the company’s stock worth $32,000 after acquiring an additional 200 shares during the last quarter. AlphaMark Advisors LLC purchased a new position in shares of Merck & Co., Inc. during the fourth quarter worth approximately $34,000. Valued Wealth Advisors LLC purchased a new position in Merck & Co., Inc. in the 4th quarter valued at $42,000. TFO Wealth Partners LLC grew its position in Merck & Co., Inc. by 108.1% in the 3rd quarter. TFO Wealth Partners LLC now owns 464 shares of the company’s stock valued at $48,000 after buying an additional 241 shares during the last quarter. Finally, Ameliora Wealth Management Ltd. purchased a new position in Merck & Co., Inc. in the 3rd quarter valued at $50,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

MRK has been the subject of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $135.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, March 27th. StockNews.com raised Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 2nd. Societe Generale downgraded Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price target for the company. in a research note on Monday, March 11th. TD Cowen raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $125.00 to $135.00 in a research note on Thursday, January 4th. Finally, UBS Group boosted their target price on shares of Merck & Co., Inc. from $135.00 to $148.00 and gave the company a “buy” rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $129.71.

Check Out Our Latest Research Report on Merck & Co., Inc.

Merck & Co., Inc. Stock Down 0.5 %

Merck & Co., Inc. stock traded down $0.64 during midday trading on Tuesday, hitting $130.35. 6,550,741 shares of the company were exchanged, compared to its average volume of 8,717,681. The company’s fifty day moving average price is $125.24 and its 200-day moving average price is $113.04. The company has a market cap of $330.13 billion, a PE ratio of 935.21, a price-to-earnings-growth ratio of 0.52 and a beta of 0.38. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.25 and a quick ratio of 1.00. Merck & Co., Inc. has a fifty-two week low of $99.14 and a fifty-two week high of $133.10.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its earnings results on Thursday, February 1st. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.12. Merck & Co., Inc. had a return on equity of 9.33% and a net margin of 0.61%. The company had revenue of $14.63 billion for the quarter, compared to analyst estimates of $14.49 billion. During the same period in the prior year, the company posted $1.62 EPS. Merck & Co., Inc.’s quarterly revenue was up 5.8% on a year-over-year basis. On average, research analysts predict that Merck & Co., Inc. will post 8.59 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 5th. Shareholders of record on Friday, March 15th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 2.36%. The ex-dividend date is Thursday, March 14th. Merck & Co., Inc.’s payout ratio is 2,200.00%.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, insider Joseph Romanelli sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total value of $124,890.00. Following the transaction, the insider now directly owns 19,569 shares of the company’s stock, valued at approximately $2,443,972.41. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, insider Joseph Romanelli sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total transaction of $124,890.00. Following the sale, the insider now directly owns 19,569 shares of the company’s stock, valued at approximately $2,443,972.41. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Steven Mizell sold 50,694 shares of the company’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $126.65, for a total value of $6,420,395.10. Following the sale, the executive vice president now directly owns 23,619 shares in the company, valued at $2,991,346.35. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by corporate insiders.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Further Reading

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.